The rounds this investor is named on, who it invests beside, and where it shows up.
Named on 10 rounds in the feed, most often at Series D+ and in Fintech.
Venture capitalblueowl.comRounds from 2023-12-20 to 2026-07-30
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
CAIS CAIS offers a platform for independent financial advisors to access alternative investments and structured notes. | Series D Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $170M | 2026-07-30 | [ PART ] |
Series D Developing, 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. |
| $154.4M |
| 2026-02-25 |
| [ PART ] |
Vestwell Workplace Retirement & Savings Platform | Series E Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $385M | 2026-02-18 | [ LEAD ] |
Crusoe An AI data-center builder | Series E Verified against 1 of 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $1.4B | 2025-10-24 | [ PART ] |
ELECTRA Therapeutics Electra Therapeutics develops SIRP-directed therapies designed to improve outcomes for patients with immune-mediated diseases and cancer. | Series C Verified against 1 of 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $183M | 2025-10-22 | [ PART ] |
STAR Therapeutics They develop and provide antibody therapies for patients with serious diseases. | Series D Verified against 2 of 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $125M | 2025-09-30 | [ PART ] |
Juniper Square Juniper Square provides a fund operating system designed for private markets, offering solutions for investor relations, finance, reporting, and fund administration to general partners (GPs) and limited partners (LPs). | Series D Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $130M | 2025-06-17 | [ PART ] |
Latigo Biotherapeutics Latigo is a clinical-stage biopharmaceutical company developing innovative non-opioid pain medicines. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $150M | 2025-03-17 | [ LEAD ] |
AlphaSense AlphaSense sells a market intelligence platform powered by AI, primarily for corporate and financial analysis. | Funding round Verified against 1 of 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $650M | 2024-06-11 | [ PART ] |
Vestwell Workplace Retirement & Savings Platform | Series D Developing, 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $125M | 2023-12-20 | [ PART ] |